Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Positive Trading Update

5 Feb 2009 07:00

RNS Number : 8208M
Intercede Group PLC
05 February 2009
 



FEBRUARY 2009

INTERCEDE GROUP plc

("Intercede" or the "Company")

Positive Trading Update

 

Intercede, the producer of the MyID Identity and Credential Management System (IDCMS) software, today announces that, based on unaudited management accounts for the 10 months to January 2009, the Company's  sales revenues are ahead of management expectations having already reached the £4.0m level. 

 

This represents a 60% increase in sales revenues for the 4 months to January 2009 when compared to the whole of the second half of the previous financial year. It also means that Intercede will achieve full year revenue growth of at least 40%. The Company continues to trade profitably and is generating positive cashflow on a month by month basis. With 2 more months remaining in the current financial year, the full year outcome will be dependent upon the timing of receipt of further orders and the Company's subsequent ability to deliver and recognise revenues in accordance with its accounting policy. 

 

A further update will be issued in early April 2009, following the end of the Company's financial year.

 

"Our leadership in the Identity and Credential Market is now starting to translate into increased shareholder value", said Richard Parris, Intercede's Chairman and Chief Executive. "As highlighted in recent announcements, Intercede continues to build momentum in the industry. We expect this trend to continue through to the end of the current period and beyond."

 

About Intercede

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalization, issuance and management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a programme with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

 

For more information visit http://www.intercede.com

 

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

Pelham Public Relations

Tel. +44 (0)20 7743 6679

Archie Berens

Robert Koh

KBC Peel Hunt

Tel. + 44 (0)20 7418 8900

Richard Kauffer

Daniel Harris

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTCKQKNOBKDKBK
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.